2019 Severe Combined Immune Deficiency Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 54 pages | ID: 2B56B27AC9DEN
VPAResearch

Abstracts

The global clinical trial report- “2019 Severe Combined Immune Deficiency Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Severe Combined Immune Deficiency. It presents in-depth analysis of Severe Combined Immune Deficiency clinical trials across markets and companies. The research work is for providing complete understanding into trends in Severe Combined Immune Deficiency.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Severe Combined Immune Deficiency clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Severe Combined Immune Deficiency

The research work is prepared through extensive and continuous research on Severe Combined Immune Deficiency trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Severe Combined Immune Deficiency patients are identified
• The report includes panorama of Severe Combined Immune Deficiency clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Severe Combined Immune Deficiency clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Severe Combined Immune Deficiency Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Severe Combined Immune Deficiency Clinical Trials by Region
  2.2.2 Average Enrollment of Severe Combined Immune Deficiency Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Severe Combined Immune Deficiency Treatment, 2019

3. REGION WISE SEVERE COMBINED IMMUNE DEFICIENCY CLINICAL TRIALS

3.1 Asia Pacific Severe Combined Immune Deficiency Clinical Trials by Country
3.2 Europe Severe Combined Immune Deficiency Clinical Trials by Country
3.3 North America Severe Combined Immune Deficiency Clinical Trials by Country
3.4 Middle East and Africa Severe Combined Immune Deficiency Clinical Trials by Country
3.5 South and Central America Severe Combined Immune Deficiency Clinical Trials by Country

4. SEVERE COMBINED IMMUNE DEFICIENCY CLINICAL TRIAL TRENDS

4.1 Start Year wise Severe Combined Immune Deficiency Clinical Trials
4.2 Phase wise Severe Combined Immune Deficiency Clinical Trials
4.3 Trial Status wise Severe Combined Immune Deficiency Clinical Trials
4.4 Trial Type wise Severe Combined Immune Deficiency Clinical Trials

5. SEVERE COMBINED IMMUNE DEFICIENCY AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Severe Combined Immune Deficiency Trials by Year
5.2 Average Enrollment in Severe Combined Immune Deficiency Trials by Phase
5.3 Average Enrollment in Severe Combined Immune Deficiency Trials by Status
5.4 Average Enrollment in Severe Combined Immune Deficiency Trials by Type of Trial

6. COMPANIES PARTICIPATING IN SEVERE COMBINED IMMUNE DEFICIENCY CLINICAL TRIALS

6.1 Severe Combined Immune Deficiency Trials by Sponsor Type
6.2 Severe Combined Immune Deficiency Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Severe Combined Immune Deficiency Trials- Phase
7.2 Severe Combined Immune Deficiency Trials- Phase
7.3 Severe Combined Immune Deficiency Trials- Phase
7.4 Severe Combined Immune Deficiency Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Severe Combined Immune Deficiency Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Figure 5: Europe – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Figure 7: North America – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Figure 9: Severe Combined Immune Deficiency Clinical Trials by Phase
Figure 10: Severe Combined Immune Deficiency Clinical Trials by Trial Status
Figure 11: Severe Combined Immune Deficiency Clinical Trials by Type
Figure 12: Severe Combined Immune Deficiency Clinical Trials by Sponsor Type
Figure 13: Severe Combined Immune Deficiency Clinical Trials by Leading Sponsors
Figure 14: Severe Combined Immune Deficiency Average Enrollment by Phase
Figure 15: Severe Combined Immune Deficiency Average Enrollment by Trial Status
Figure 16: Severe Combined Immune Deficiency Average Enrollment by Type
Figure 17: Severe Combined Immune Deficiency- Average Enrolment by Type of Sponsors
Figure 18: Severe Combined Immune Deficiency- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Severe Combined Immune Deficiency Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Table 5: Europe – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Table 7: North America – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Severe Combined Immune Deficiency Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Severe Combined Immune Deficiency Average Enrollment by Phase
Table 15: Severe Combined Immune Deficiency Average Enrollment by Trial Status
Table 16: Severe Combined Immune Deficiency Average Enrollment by Type
Table 17: Severe Combined Immune Deficiency- Average Enrolment by Type of Sponsors
Table 18: Severe Combined Immune Deficiency- Enrolment by Leading Sponsors